Contact Information: Contact: Kelle Straw Merial 678-638-3690 Email Contact Rick Rountree SCYNEXIS 919-878-1144 Email Contact
Merial-SCYNEXIS Research Collaboration Expanded
| Quelle: SCYNEXIS, INC.
DULUTH, GA, and RESEARCH TRIANGLE PARK, NC -- (MARKET WIRE) -- May 15, 2007 -- Merial Limited
and SCYNEXIS, Inc. announced today that they have expanded the scope of
their research collaboration as a result of the success of their first
agreement which began in 2005. SCYNEXIS, a primary drug discovery and
development company and collaborator with Merial, will, under the terms of
a new multi-year agreement, significantly increase the capacity of their
technologically advanced biological screening, bioanalytical, ADMET and
medicinal chemistry efforts directed towards Merial projects.
"Merial is very pleased to collaborate with SCYNEXIS to further expand our
ability to identify and optimize novel active compounds that will form the
basis of new products designed to meet our customers' future needs," states
Dr. Kevin Schultz, Chief Scientific Officer and Head of Global R&D.
"Innovation-driven companies such as Merial are constantly exploring new
products that will meet the demands of the growing animal health market.
Collaborating with drug discovery and development companies such as
SCYNEXIS can offer novel opportunities to provide new pharmaceuticals to a
wide range of companion and production animal species. This new
collaboration will allow for faster delivery of novel drugs to Merial that
will further impact this dynamic market," said SCYNEXIS President and CEO
Dr. Yves Ribeill.
About Merial
Merial is a world-leading, innovation-driven animal health company,
providing a comprehensive range of products to enhance the health,
well-being and performance of a wide range of animals. Merial employs
approximately 5,000 people and operates in more than 150 countries
worldwide. Its 2006 sales were nearly $2.2 billion. Merial Limited is a
joint venture between Merck & Co., Inc. and sanofi-aventis. For more
information, please see www.merial.com.
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company headquartered
in Research Triangle Park, North Carolina. Our mission is to be the leader
in delivering effective and innovative drug pipeline solutions to our
pharmaceutical partners.
SCYNEXIS research teams integrate medicinal chemistry, biological
screening, computational chemistry, bioanalysis and analytical chemistry
which use powerful, proprietary technologies such as the HEOS® Software
Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to
advance molecules to candidate selection. We have tailored our development
teams to be especially effective in moving customer projects from the
discovery phase to the clinic. Our process chemistry and bioanalytical
departments operate under current GMP/GLP guidelines and have a strong
track record of success. Our website is located at www.scynexis.com
®HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc. and
™KIT Kinase Inhibitor Technology is a trademark of SCYNEXIS, Inc.